Kisunla: Uses, How It Works, And Common Side Effects

Kisunla is an intravenous infusion used to treat patients with Alzheimer’s disease who have mild cognitive impairment or mild dementia stage of disease. It was approved by the FDA in 2024.

This medication is a plaque-targeting therapy that helps to slow down the decline in memory, thinking, and daily functioning. It is an antibody that works by helping the body remove amyloid plaques in the brain, which are thought to contribute to Alzheimer’s disease symptoms by disrupting brain cell function. Kisunla is not a cure for Alzheimer’s disease.

Kisunla is given as a once-monthly intravenous infusion by a healthcare provider. Each infusion takes approximately 30 minutes.

Common side effects of Kisunla include headache, infusion-related reactions, and swelling in areas of the brain with or without small spots of bleeding in or on the brain's surface.

This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Always consult with your healthcare provider.